[Comparative in vitro effect of 7 quinolones on Ureaplasma urealyticum].
Some new quinolones may be used for the treatment of gonococcal urethritis. U. urealyticum is considered as a potential agent of urethritis. This report describes the in vitro antimicrobial activity of seven quinolones against 45 clinical isolates of U. urealyticum. The MIC's geometric mean is (microgram/ml): rosoxacin (1,74), pefloxacin (4,6), oxolinic acid (9), flumequin (12,12), norfloxacin (15,75), nalidixic acid (27). Pipemidic acid is constantly inactive (greater than 128 micrograms/ml). The results of these susceptibility studies provide support for undertaking clinical evaluations of new quinolones against infections with U. urealyticum.
D042462:4-Quinolones; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024841:Fluoroquinolones; D009268:Nalidixic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D009643:Norfloxacin; D010093:Oxolinic Acid / Q000494:pharmacology; D015366:Pefloxacin; D010876:Pipemidic Acid / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology*; D011807:Quinolizines / Q000494:pharmacology; D015363:Quinolones; D014509:Ureaplasma / Q000187:drug effects*
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D011804:Quinolines; D011807:Quinolizines; D015363:Quinolones; D015366:Pefloxacin; D009268:Nalidixic Acid; C021083:rosoxacin; D010093:Oxolinic Acid; D010876:Pipemidic Acid; D009643:Norfloxacin; C012976:flumequine
Activité comparée in vitro de sept quinolones sur Ureaplasma urealyticum.